Carol Moreno

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8748525/publications.pdf

Version: 2024-02-01

105 papers	5,961 citations	147801 31 h-index	74163 75 g-index
105 all docs	105 docs citations	105 times ranked	4451 citing authors

#	Article	IF	Citations
1	Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. Transplantation and Cellular Therapy, 2022, 28, 43.e1-43.e5.	1.2	10
2	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leukemia and Lymphoma, 2022, 63, 1375-1386.	1.3	8
3	First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica, 2022, 107, 2108-2120.	3.5	53
4	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood, 2022, 139, 3278-3289.	1.4	83
5	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaÂ. Blood Advances, 2022, 6, 3440-3450.	5.2	91
6	Longâ€term efficacy of firstâ€line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: aâ€‰pooled analysis from four clinical trials. British Journal of Haematology, 2022, 196, 947-953.	2.5	28
7	Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. , 2022, 1, .		66
8	Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study.. Journal of Clinical Oncology, 2022, 40, 7519-7519.	1.6	4
9	Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. Annals of Hematology, 2021, 100, 1733-1742.	1.8	10
10	Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.. Journal of Clinical Oncology, 2021, 39, 7501-7501.	1.6	16
11	Autoimmune cytopenia and CLL ride together. Blood, 2021, 137, 3464-3465.	1.4	3
12	Autoimmune Cytopenia in CLL. Cancer Journal (Sudbury, Mass), 2021, 27, 286-296.	2.0	5
13	The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. Current Opinion in Oncology, 2021, 33, 670-680.	2.4	6
14	Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. Journal of Experimental and Clinical Cancer Research, 2021, 40, 321.	8.6	15
15	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Journal of Clinical Oncology, 2021, 39, 3853-3865.	1.6	115
16	Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study. Blood, 2021, 138, 1561-1561.	1.4	1
17	First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study. Blood, 2021, 138, 70-70.	1.4	20
18	MRD in CLL: some answers, many questions. Blood, 2021, 138, 2746-2747.	1.4	2

#	Article	IF	Citations
19	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia, 2020, 34, 787-798.	7.2	321
20	When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine). Annals of Hematology, 2020, 99, 157-165.	1.8	7
21	Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. Hematology American Society of Hematology Education Program, 2020, 2020, 33-40.	2.5	9
22	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research, 2020, 26, 2096-2103.	7.0	31
23	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica, 2020, 105, e164-e168.	3.5	5
24	FcÎ³RIIb-BCR coligation inhibits BCR signaling in chronic lymphocytic leukemia. Haematologica, 2020, 106, 306-309.	3.5	1
25	Gene expression workflow to analyze residual leukemic cells in Chronic Lymphocytic Leukemia. International Journal of Laboratory Hematology, 2020, 42, 423-430.	1.3	0
26	Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 548-555.e4.	0.4	10
27	Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib. Blood, 2020, 136, 32-33.	1.4	6
28	Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials. Blood, 2020, 136, 23-24.	1.4	19
29	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood, 2020, 136, 16-17.	1.4	32
30	Challenges and Solutions for Collecting and Analyzing Real World Data: The Eric CLL Database as an Illustrative Example. HemaSphere, 2020, 4, e425.	2.7	2
31	Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE). Blood, 2020, 136, 25-26.	1.4	4
32	Changes in clinical stage identify patients with <scp>CLL</scp> and different outcome within iw<scp>CLL</scp> partial response: <scp>RESONATE</scp> study. British Journal of Haematology, 2019, 185, 148-150.	2.5	2
33	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 715-722.e6.	0.4	35
34	Final analysis from RESONATE: Up to six years of followâ€up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 2019, 94, 1353-1363.	4.1	305
35	Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2823-2834.	2.5	7
36	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood, 2019, 133, 2031-2042.	1.4	178

#	Article	IF	Citations
37	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Advances, 2019, 3, 1799-1807.	5.2	90
38	CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. Cytometry Part B - Clinical Cytometry, 2019, 96, 143-148.	1.5	26
39	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 43-56.	10.7	448
40	Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.. Journal of Clinical Oncology, 2019, 37, 7510-7510.	1.6	1
41	Chromosome Banding Analysis Versus Genomic Microarrays: A Comparison of Methods for Genomic Complexity Risk Stratification in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. Blood, 2019, 134, 4287-4287.	1.4	1
42	Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC). Blood, 2019, 134, 4296-4296.	1.4	2
43	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica, 2018, 103, 1209-1217.	3.5	30
44	Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica, 2018, 103, 698-706.	3.5	63
45	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplantation, 2018, 53, 255-263.	2.4	14
46	Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. British Journal of Haematology, 2018, 180, 666-679.	2.5	51
47	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry Part B - Clinical Cytometry, 2018, 94, 121-128.	1.5	133
48	Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 737-742.	0.4	1
49	Safety Analysis of Four Randomized ControlledÂStudies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 648-657.e15.	0.4	62
50	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood, 2018, 132, 892-902.	1.4	83
51	Singleâ€agent ibrutinib versus chemoimmunotherapy regimens for treatmentâ€naÃ¯ve patients with chronic lymphocytic leukemia: A crossâ€trial comparison of phase 3 studies. American Journal of Hematology, 2018, 93, 1402-1410.	4.1	24
52	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 803-813.e7.	0.4	32
53	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica, 2018, 103, 1502-1510.	3.5	111
54	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. Blood, 2018, 132, 5565-5565.	1.4	3

#	Article	IF	Citations
55	Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE. Blood, 2018, 132, 691-691.	1.4	8
56	Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. Blood, 2018, 132, 1856-1856.	1.4	2
57	The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.. Journal of Clinical Oncology, 2018, 36, 7533-7533.	1.6	1
58	Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).. Journal of Clinical Oncology, 2018, 36, 7521-7521.	1.6	0
59	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12Âyears follow-up of a phase 2 trial. Annals of Hematology, 2017, 96, 639-646.	1.8	7
60	Centre characteristics and procedureâ€related factors have an impact on outcomes of allogeneic transplantation for patients with <scp>CLL</scp>: a retrospective analysis from the European Society for Blood and Marrow Transplantation (<scp>EBMT</scp>). British Journal of Haematology, 2017, 178, 521-533.	2.5	26
61	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 2017, 129, 2612-2615.	1.4	111
62	Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance. American Journal of Hematology, 2017, 92, E132-E135.	4.1	1
63	FcÎ³RIIb expression in early stage chronic lymphocytic leukemia. Leukemia and Lymphoma, 2017, 58, 2642-2648.	1.3	7
64	Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions. Oncotarget, 2017, 8, 54297-54303.	1.8	44
65	Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?. Haematologica, 2016, 101, 263-265.	3.5	19
66	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2117-2125.	2.0	87
67	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood, 2016, 128, 234-234.	1.4	36
68	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood, 2016, 128, 4383-4383.	1.4	7
69	Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2016, 128, 4663-4663.	1.4	0
70	Changes in Clinical Stage Identify Different Response Categories Among Patients in Iwcll PR: Analysis of CLL Patients on the Resonate Study. Blood, 2016, 128, 4384-4384.	1.4	0
71	Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT. Blood, 2016, 128, 3504-3504.	1.4	0
72	Chronic lymphocytic leukemia and the Warburg effect. Blood, 2015, 125, 3368-3369.	1.4	12

#	Article	IF	Citations
73	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood, 2015, 126, 1921-1924.	1.4	197
74	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica, 2015, 100, 511-516.	3.5	42
75	Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis. Blood, 2015, 126, 3209-3209.	1.4	1
76	Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project. Blood, 2015, 126, 4146-4146.	1.4	2
77	Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2015, 33, 7012-7012.	1.6	3
78	Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naÃ¯ve CLL/SLL (PCYC-1130): iLLUMINATE.. Journal of Clinical Oncology, 2015, 33, TPS7095-TPS7095.	1.6	6
79	Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. Mediators of Inflammation, 2014, 2014, 1-7.	3.0	16
80	B cell activation through <scp>CD</scp>40 and <scp>IL</scp>4R ligation modulates the response of chronic lymphocytic leukaemia cells to <scp>BAFF</scp> and <scp>APRIL</scp>. British Journal of Haematology, 2014, 164, 570-578.	2.5	32
81	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. New England Journal of Medicine, 2014, 371, 213-223.	27.0	1,427
82	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. Blood, 2014, 124, 3841-3849.	1.4	185
83	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2014, 124, 3331-3331.	1.4	24
84	Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2014, 124, 4696-4696.	1.4	12
85	A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. Blood, 2014, 124, 1976-1976.	1.4	2
86	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3300-3300.	1.4	0
87	A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study. Blood, 2013, 122, 1645-1645.	1.4	2
88	Long-Term Follow-Up Of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation For High Risk Follicular Lymphoma. Blood, 2013, 122, 5519-5519.	1.4	0
89	Prognostic Assessment In Patients With Chronic Lymphocytic Leukemia (CLL) In Clinical Practice: A European Research Initiative On CLL (ERIC) Survey. Blood, 2013, 122, 4156-4156.	1.4	1
90	Comment on â€œSoluble BAFF Levels Inversely Correlate with Peripheral B Cell Numbers and the Expression of BAFF Receptorsâ€. Journal of Immunology, 2012, 188, 2930.2-2931.	0.8	5

#	Article	IF	Citations
91	Rituximab in Combination with Bendamustine or Chlorambucil for Treating Patients with Chronic Lymphocytic Leukemia: Interim Results of a Phase IIIb Study (MaBLe).. Blood, 2012, 120, 2744-2744.	1.4	16
92	Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 2064-2068.	1.3	16
93	Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica, 2011, 96, 752-761.	3.5	117
94	Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood, 2010, 116, 4771-4776.	1.4	126
95	Is MRD eradication a desirable goal in CLL?. Best Practice and Research in Clinical Haematology, 2010, 23, 97-107.	1.7	6
96	B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. Leukemia and Lymphoma, 2009, 50, 1075-1082.	1.3	20
97	Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital ClÃnic of Barcelona experience. Blood, 2009, 114, 2044-2050.	1.4	132
98	In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood, 2009, 114, 4832-4842.	1.4	132
99	The Prognostic Significance of Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 2361-2361.	1.4	0
100	New prognostic markers in chronic lymphocytic leukemia. Blood Reviews, 2008, 22, 211-219.	5.7	118
101	A Different Ontogenesis for CLL Cases Carrying Stereotyped Antigen Receptors: Molecular and Computational Evidence. Blood, 2008, 112, 777-777.	1.4	0
102	Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood, 2006, 107, 4563-4569.	1.4	130
103	Over 20% of Patients with Chronic Lymphocytic Leukemia Carry Stereotyped Receptors: Pathogenetic Implications and Clinical Correlations.. Blood, 2006, 108, 26-26.	1.4	1
104	Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 3433-3438.	1.6	137
105	Nucleotide Insertions and Deletions in Chronic Lymphocytic Leukemia. A CLL Specific Deletion among IGHV3-21 Expressing Cases with Stereotyped Receptors.. Blood, 2005, 106, 2100-2100.	1.4	0